Atopic dermatitis and skin allergies - Update and outlook

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 12, 2013, Pages 1509-1519

  Wollenberg, A ^a   Feichtner, K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

atopic dermatitis; chronic urticaria; drug allergy

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ANESTHETIC AGENT; BETA LACTAM ANTIBIOTIC; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CANNABIS; CARBOPLATIN; CETIRIZINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUTICASONE PROPIONATE; IBUPROFEN; LATEX; METHYLPREDNISOLONE ACEPONATE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; OMALIZUMAB; OXALIPLATIN; PACLITAXEL; PARACETAMOL; PIMECROLIMUS; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RITUXIMAB; SULFONAMIDE; TACROLIMUS; UNINDEXED DRUG;

ACUPUNCTURE; ADAPTIVE IMMUNITY; ANAPHYLACTIC SHOCK; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DESENSITIZATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; FIXED DRUG ERUPTION; HEALTH CARE COST; HUMAN; HYPER IGE SYNDROME; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; KERATINOCYTE; LACTOBACILLUS RHAMNOSUS; LARYNX EDEMA; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SCORING SYSTEM; SKIN ALLERGY; SKIN TEST; TH2 CELL; URTICARIA;

ATOPIC DERMATITIS; CHRONIC URTICARIA; DRUG ALLERGY;

ADAPTIVE IMMUNITY; DERMATITIS, ATOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFECTION; SKIN DISEASES;

EID: 84889608475     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12324     Document Type: Review

References (102)

1. Novak N, Simon D,. Atopic dermatitis-from new pathophysiologic insights to individualized therapy. Allergy 2011; 66: 830-839.
2. von Gunten S, Marsland BJ, von Garnier C, Simon D,. Update in clinical allergy and immunology. Allergy 2012; 67: 1491-1500.
3. Bieber T,. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
4. Eyerich K, Novak N,. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013; 68: 974-982.
5. Bieber T,. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012; 67: 1475-1482.
6. Apfelbacher CJ, Diepgen TL, Schmitt J,. Determinants of eczema: population-based cross-sectional study in Germany. Allergy 2011; 66: 206-213.
7. Feary J, Britton J, Leonardi-Bee J,. Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy 2011; 66: 569-578.
8. Kiraly N, Benn CS, Biering-Sorensen S, Rodrigues A, Jensen KJ, Ravn H, et al. Vitamin A supplementation and BCG vaccination at birth may affect atopy in childhood: long-term follow-up of a randomized controlled trial. Allergy 2013; 68: 1168-1176.
9. Ballardini N, Kull I, Lind T, Hallner E, Almqvist C, Ostblom E, et al. Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy 2012; 67: 537-544.
10. Boyle RJ, Ismail IH, Kivivuori S, Licciardi PV, Robins-Browne RM, Mah LJ, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy 2011; 66: 509-516.
11. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68: 498-506.
12. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB,. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007; 157: 645-648.
13. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J,. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.
14. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011; 66: 1114-1121.
15. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-1117.
16. Bieber T, Cork M, Reitamo S,. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012; 67: 969-975.
17. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129: 1892-1908.
18. Gschwandtner M, Mildner M, Mlitz V, Gruber F, Eckhart L, Werfel T, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013; 68: 37-47.
19. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
20. Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118: 214-219.
21. Thyssen JP, Linneberg A, Johansen JD, Carlsen BC, Zachariae C, Meldgaard M, et al. Atopic diseases by filaggrin mutations and birth year. Allergy 2012; 67: 705-708.
22. Zhang H, Guo Y, Wang W, Shi M, Chen X, Yao Z,. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis. Allergy 2011; 66: 420-427.
23. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150-155.
24. Kezic S, O'Regan GM, Yau N, Sandilands A, Chen H, Campbell LE, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy 2011; 66: 934-940.
25. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127: 773-786.
26. Wollenberg A, Rawer HC, Schauber J,. Innate immunity in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 272-281.
27. Wollenberg A, Bieber T,. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205-213.
28. Bieber T,. Many ways lead to Rome: a glance at the multiple immunological pathways underlying atopic dermatitis. Allergy 2013; 68: 957-958.
29. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992; 175: 1285-1290.
30. Maurer D, Fiebiger E, Ebner C, Reininger B, Fischer GF, Wichlas S, et al. Peripheral blood dendritic cells express FcεRI as a complex composed of FcεRIα and FcεRIγ-Chains and can use this Receptor for IgE-mediated Allergen presentation. J Immunol 1996; 157: 607-616.
31. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wüthrich B,. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-849.
32. Liang Y, Wang P, Zhao M, Liang G, Yin H, Zhang G, et al. Demethylation of the FCER1G promoter leads to FcepsilonRI overexpression on monocytes of patients with atopic dermatitis. Allergy 2012; 67: 424-430.
33. Ohman S, Johansson SGO,. Immunoglobulins in atopic dermatitis, with special reference to IgE. Acta Derm Venereol (Stockh) 1974; 54: 193-202.
34. Oppel T, Schuller E, Gunther S, Moderer M, Haberstok J, Bieber T, et al. Phenotyping of epidermal dendritic cells allows the differentiation between extrinsic and intrinsic forms of atopic dermatitis. Br J Dermatol 2000; 143: 1193-1198.
35. Salt BH, Boguniewicz M, Leung DY,. Severe refractory atopic dermatitis in adults is highly atopic. J Allergy Clin Immunol 2007; 119: 508-509.
36. Dondi A, Ricci L, Neri I, Ricci G, Patrizi A,. The switch from non-IgE-associated to IgE-associated atopic dermatitis occurs early in life. Allergy 2013; 68: 259-260.
37. Benson AA, Toh JA, Vernon N, Jariwala SP,. The role of vitamin D in the immunopathogenesis of allergic skin diseases. Allergy 2012; 67: 296-301.
38. Kanda N, Hau CS, Tada Y, Sato S, Watanabe S,. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: relationship between IL-31 and oncostatin M. Allergy 2012; 67: 804-812.
39. Hartmann B, Heine G, Babina M, Steinmeyer A, Zugel U, Radbruch A, et al. Targeting the vitamin D receptor inhibits the B cell-dependent allergic immune response. Allergy 2011; 66: 540-548.
40. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-417.
41. Kasraie S, Niebuhr M, Baumert K, Werfel T,. Functional effects of interleukin 31 in human primary keratinocytes. Allergy 2011; 66: 845-852.
42. Breuer K, Wittmann M, Bosche B, Kapp A, Werfel T,. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551-555.
43. Niebuhr M, Langnickel J, Draing C, Renz H, Kapp A, Werfel T,. Dysregulation of toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008; 63: 728-734.
44. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-859.
45. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation. Allergy 2011; 66: 351-359.
46. Wollenberg A, Wetzel S, Burgdorf WH, Haas J,. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667-674.
47. Yoon M, Spear PG,. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 2002; 76: 7203-7208.
48. Wollenberg A, Wagner M, Günther S, Towarowski A, Tuma E, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-1102.
49. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.
50. Leung DY, Gao PS, Grigoryev DN, Rafaels NM, Streib JE, Howell MD, et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 2011; 127: 965-973.
51. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B,. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
52. Hinz T, Zaccaro D, Byron M, Brendes K, Krieg T, Novak N, et al. Atopic dermo-respiratory syndrome is a correlate of eczema herpeticum. Allergy 2011; 66: 925-933.
53. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-328.
54. Vlieg-Boerstra BJ, van de Weg WE, van der Heide S, Dubois AE,. Where to prick the apple for skin testing? Allergy 2013; 68: 1196-1198.
55. Wollenberg A, Vogel S,. Patch testing for noncontact dermatitis: the atopy patch test for food and inhalants. Curr Allergy Asthma Rep 2013; 13: 539-544.
56. Kerschenlohr K, Darsow U, Burgdorf WH, Ring J, Wollenberg A,. Lessons from atopy patch testing in atopic dermatitis. Curr Allergy Asthma Rep 2004; 4: 285-289.
57. Wistokat-Wulfing A, Schmidt P, Darsow U, Ring J, Kapp A, Werfel T,. Atopy patch test reactions are associated with T lymphocyte-mediated allergen-specific immune responses in atopic dermatitis. Clin Exp Allergy 1999; 29: 513-521.
58. Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wuthrich B, et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004; 59: 1318-1325.
59. Nocerino R, Granata V, Di Costanzo M, Pezzella V, Leone L, Passariello A, et al. Atopy patch tests are useful to predict oral tolerance in children with gastrointestinal symptoms related to non-IgE-mediated cow's milk allergy. Allergy 2013; 68: 246-248.
60. Wollenberg A, Boos A, Langenbeck A, Heinz V, Spielberger BD, Schimke LF, et al. Allergic and immunodeficiency findings in atopic dermatitis and hyper-IgE syndrome patients-recommendations for a clinical workup. Chem Immunol Allergy 2014 (in press).
61. Schimke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol 2010; 126: 611-617.
62. Wollenberg A, Schnopp C,. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 351-368.
63. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. Difficult to control atopic dermatitis. World Allergy Organ J 2013; 6: 6.
64. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61: 202-205.
65. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060.
66. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-1193.
67. Jensen JM, Scherer A, Wanke C, Brautigam M, Bongiovanni S, Letzkus M, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012; 67: 413-423.
68. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A,. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 137-143.
69. Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU,. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 2005; 60: 944-951.
70. Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742-750.
71. Wollenberg A, Bieber T,. Proactive therapy of atopic dermatitis-an emerging concept. Allergy 2009; 64: 276-278.
72. Wollenberg A, Ehmann LM,. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24: 253-260.
73. Ohsawa Y, Hirasawa N,. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012; 67: 1014-1022.
74. Pfab F, Kirchner MT, Huss-Marp J, Schuster T, Schalock PC, Fuqin J, et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient- and examiner-blinded, randomized, placebo-controlled, crossover trial. Allergy 2012; 67: 566-573.
75. Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara Y, Moroi Y, et al. Topical application of PPARalpha (but not beta/delta or gamma) suppresses atopic dermatitis in NC/Nga mice. Allergy 2012; 67: 936-942.
76. Schnuch A, Geier J, Lessmann H, Arnold R, Uter W,. Surveillance of contact allergies: methods and results of the Information Network of Departments of Dermatology (IVDK). Allergy 2012; 67: 847-857.
77. Thyssen JP, Johansen JD, Linneberg A, Menne T, Engkilde K,. The association between contact sensitization and atopic disease by linkage of a clinical database and a nationwide patient registry. Allergy 2012; 67: 1157-1164.
78. Baeck M, Goossens A,. Systemic contact dermatitis to corticosteroids. Allergy 2012; 67: 1580-1585.
79. Gaffal E, Cron M, Glodde N, Tuting T,. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy 2013; 68: 994-1000.
80. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011; 66: 317-330.
81. Ben-Shoshan M, Blinderman I, Raz A,. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy 2013; 68: 131-141.
82. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011; 66: 840-844.
83. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M,. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921-928.
84. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P,. Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66: 303-305.
85. Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M,. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 2013; 68: 229-235.
86. Takeda T, Sakurai Y, Takahagi S, Kato J, Yoshida K, Yoshioka A, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66: 428-433.
87. Krause K, Grattan CE, Bindslev-Jensen C, Gattorno M, Kallinich T, de Koning HD, et al. How not to miss autoinflammatory diseases masquerading as urticaria. Allergy 2012; 67: 1465-1474.
88. Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K,. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013; 68: 816-819.
89. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68: 27-36.
90. Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; 66: 1538-1545.
91. Dona I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondon C, Campo P, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy 2011; 66: 1428-1433.
92. Hashizume H, Fujiyama T, Kanebayashi J, Kito Y, Hata M, Yagi H,. Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy. Allergy 2013; 68: 681-689.
93. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions-an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844-852.
94. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013; 68: 853-861.
95. Renaudin JM, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin DA,. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy 2013; 68: 929-937.
96. Sala Cunill A, Labrador-Horrillo M, Guilarte M, Luengo O, Cardona V,. Generalised delayed desquamative exanthema after intradermal testing with betalactam antibiotics. Allergy 2011; 66: 702-703.
97. Ebo DG, Leysen J, Mayorga C, Rozieres A, Knol EF, Terreehorst I,. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011; 66: 1275-1286.
98. Aranda A, Mayorga C, Ariza A, Dona I, Rosado A, Blanca-Lopez N, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011; 66: 247-254.
99. Daubner B, Groux-Keller M, Hausmann OV, Kawabata T, Naisbitt DJ, Park BK, et al. Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells. Allergy 2012; 67: 58-66.
100. Cornejo-Garcia JA, Gueant-Rodriguez RM, Torres MJ, Blanca-Lopez N, Tramoy D, Romano A, et al. Biological and genetic determinants of atopy are predictors of immediate-type allergy to betalactams Spain. Allergy 2012; 67: 1181-1185.
101. Bursztejn AC, Romano A, Gueant-Rodriguez RM, Cornejo JA, Oussalah A, Chery C, et al. Allergy to betalactams and nucleotide-binding oligomerization domain (NOD) gene polymorphisms. Allergy 2013; 68: 1076-1080.
102. Waton J, Pouget-Jasson C, Loos-Ayav C, Trechot P, Bursztejn AC, Schmutz JL, et al. Drug re-challenges in cutaneous adverse drug reactions: information and effectiveness in the long-term management of patients. Allergy 2011; 66: 941-947.